DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...
22hon MSN
DexCom projects 15% revenue growth for 2025 while advancing type 2 diabetes market coverage
Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.
Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...
Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback